Entering text into the input field will update the search result below

BioCryst: Solid Delivery And Follow Through


  • BioCryst has two approved products.
  • ORLADEYO beat street expectations today with its first full quarter revenue figures.
  • BCX9930 will start a pivotal trial soon.
  • Looking for more investing ideas like this one? Get them exclusively at The Total Pharma Tracker. Learn More »
Nothing but the best brands for their customers
Photo by AlexanderFord/E+ via Getty Images

BioCryst Pharmaceuticals (NASDAQ:BCRX) has two approved products and a diverse pipeline targeting rare diseases. ORLADEYO or berotralstat is a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older. It was

About the TPT service

Thanks for reading. At the Total Pharma Tracker, we offer the following:-

Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker and get extensive curated research material. 

For investors requiring hands-on support, our in-house experts go through our tools and find the best investible stocks, complete with buy/sell strategies and alerts.

Sign up now for our free trial, request access to our tools, and find out, at no cost to you, what we can do for you. 

This article was written by

Avisol Capital Partners is made up of a team of medical experts, finance professionals and techies, all of whom invest their own money in the picks they share. They aim to help readers find the middle ground between value and growth investing, as they demystify the biopharma industry.

They lead the investing group Total Pharma Tracker where they offer a monthly updated catalyst database, an investability scoring system for quick reference ideas, and direct access in chat for dialogue and questions. Learn more.

Analyst’s Disclosure: I/we have no positions in any stocks mentioned, but may initiate a long position in BCRX over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (6)

Return to Value profile picture
So, where are all the Stonehouse critics who were so prevalent here last year?
A biotech selling its own creation is groundbreaking....and will be very profitable.
Bought in last April, added heavily at $8, will add heavily again this summer. Expecting $20-25 by EOY. Q2 revenue will have a minimum of triple digit growth QOQ. Good luck Bulls!
ChrisForte profile picture
BCRX : BioCryst shares surge 21% on Evercore upgrade, revenue beat • 4:00 PM
BioCryst Pharmaceuticals (NASDAQ:BCRX) shares are up 21% after Evercore ISI upgraded the stock to outperform on strong Q1 results.
Analyst Liisa Bayko also upped her price target on shares to $20 from $16.
She wrote that the company "crushed" Q1 results, driven by sales of its hereditary angioedema treatment ORLADEYO (berotralstat) of $10.9M, handily beating consensus of $3.5M.
Bayko also increased her ORLADEYO 2021 sales estimate to $85M and sees a total market opportunity more than $500M.
She also notes that a phase 3 study for BCX9930 in paroxysmal nocturnal hemoglobinuria will begin in the second half of the year with data expected around 2023.
Bayko believes the potential of this candidate "could dwarf ORLADEYO."
Beadnix profile picture
I am long BCRX. Thanks for your update. Buy and hold for growth in the coming years!
pro8 profile picture
In at ~ $4 about this time last year
xXgodFatherXx profile picture
Great write up...Shorting here is Kamikazee crazy!😆
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!

About BCRX

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on BCRX

Related Stocks

SymbolLast Price% Chg
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.